Nanoparticle therapeutics in FSHD: current research and future perspectives.

Area of Science:

• Neurology
• Genetics
• Nanomedicine

Background:

• Facioscapulohumeral muscular dystrophy (FSHD) is a genetic neuromuscular disorder causing progressive muscle weakness due to DUX4 gene expression.
• Current treatments for FSHD are limited to supportive care, lacking disease-modifying options despite understanding its molecular basis.

Purpose of the Study:

• To review current FSHD therapeutics and explore the potential of nanotherapeutics for targeted muscle delivery.
• To highlight how advances in nanomedicine for other muscular dystrophies can inform FSHD treatment strategies.

Main Methods:

• Review of existing literature on FSHD treatments and nanomedicine applications in muscular dystrophies.
• Analysis of preclinical data on nanoparticle-mediated delivery systems for skeletal muscle.

Main Results:

• Nanotechnology offers promising solutions for targeted delivery of therapeutics to skeletal muscle in FSHD.
• Preclinical data from Duchenne muscular dystrophy and other muscular dystrophies support the viability of nanoparticle-based strategies.

Conclusions:

• Nanotherapeutics represent an emerging and viable approach for FSHD treatment, improving targeted delivery and bioavailability.
• Further research is needed to address challenges in nanoparticle-based approaches, including long-term safety, scalability, and efficiency for clinical translation in FSHD.